



**REGISTERED OFFICE**

**GRANULES INDIA LTD.**, 2nd Floor, 3rd Block, My Home Hub,  
Madhapur, Hyderabad - 500 081, Telangana, INDIA.  
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com  
CIN: L24110TG1991PLC012471

**Dated May 11, 2017**

To,  
National Stock Exchange of India Limited  
Bombay Stock Exchange Limited  
Symbol: NSE: GRANULES; BSE: 532482

Dear Sir,

**Sub: Presentation to the Analysts/Investors**

We refer to audited financial results for the fourth quarter and financial year ended March 31, 2017 submitted to you today, 11<sup>th</sup> May 2017.

We are now enclosing the presentation in this regard to the Analysts/Investors which is also being uploaded on our website.



This is pursuant to Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the above information on record.

Thanking you.

Yours faithfully,

**FOR, GRANULES INDIA LIMITED**

  
  
**(CHAITANYA TUMMALA)**  
**COMPANY SECRETARY &**  
**COMPLIANCE OFFICER**



**GRANULES**

**Investor Presentation: Q4FY17**




- Present across the entire pharmaceutical manufacturing value chain from active pharmaceutical ingredients (API) to pharmaceutical formulation intermediates (PFI) to finished dosages (FD) manufacturing.
- Manufacturing facilities with approvals from the US, Europe and other regulatory Agencies.
- Regulated markets of North America and Europe account for **67%** of overall revenue, while the balance comes from customers in Latin America, India and ROW countries.

Listing information : NSE	
Market Cap (INR mn) as on Mar'17	31,755
Outstanding Equity Shares (mn)	228.70
Face value of equity (INR/share)	1.0
Bloomberg code	GRAN:IN
Sector	Pharmaceuticals


Share Holding Pattern	June'16	Sept'16	Dec'16	Mar'17
Promoters Group (%)	51.1	51.0	51.9	53.4
Public (%)	48.9	49.0	48.1	46.6

- Entered potentially higher margin products through establishing in house API and Formulation research centers located at Hyderabad and in Virginia
- Acquired Auctus Pharma in 2014 with focus on development of new APIs through in-house R&D for organic ANDA filling and customers' formulation development
- Presence in potentially higher margin CRAMS business through 50-50 JV with Ajinomoto Omnicem.
- Ventured into manufacturing and marketing of OTC products to the retail chains in the US Markets
- Acquired Formulation facility in Virginia, USA to introduce value added products
- Started construction of green field manufacturing site in Vizag to enter into Oncology and specialty Business

## CORE BUSINESS



## STRATEGIC GROWTH PLANS



### CRAMS Business

**Product:** Low-volume, value added Products  
**Market:** Innovator and Brand Owner in the Regulated Markets  
**Plant Location:** Vizag

**Vertically integrated** across the entire value chain from active pharmaceutical ingredients (API) to pharmaceutical formulation intermediates (PFI) to finished dosages (FD) manufacturing of **“High Volume Products”**

Strong presence in **‘first line of defense’** products such as such as **Paracetamol, Ibuprofen, Metformin and Guaifenesin.**

**Future Growth** from existing portfolio

- **Increasing emphasis on finished dosages** will increase revenue and profitability

- Improving **efficiencies and yields**

- Growth will be driven by **larger wallet share from existing customers** as well as **new customers** additions

- Enhancing the product basket with **new ANDA filling**

Capacity augmentation of APIs in base molecules: **(under implementation)**

- Addition of **7,000 TPA in Metformin capacity** to reach to **9,000 TPA**

- Addition of **2,000 TPA in Guaifenesin capacity** to reach to **3,200 TPA**

- Addition of **6,000 TPA in Paracetamol capacity** to reach to **24,000 TPA**

Addition of **4,000 TPA PFI capacity** : **(under implementation)**

## New API Division

- Auctus Acquisition – High-potential New API business.
- Significant saving; capacities with regulatory approvals for Granules **growth strategy**.
- USFDA approved multipurpose API manufacturing facility in Vizag and an intermediate manufacturing facility in Hyderabad

## Granules Research Centre

- Established in house R&D division in Hyderabad, to develop new generic products
- Presently over **70 scientists** are working

## Granules Pharmaceuticals Inc.

- Acquired Formulation facility in Virginia, USA to introduce value added products.
- Working towards limited competition space.
- Created resources for development of 5-6 ANDAs per year.

## Granules Consumer Health

- Marketing of store brand OTC products with direct relationship with retail outlets in the US (B→B→C)
- Extension of core business with existing products in the initial stage and thereafter continuously increasing product offering by introducing new OTC products .





❑ **Foray into Contract Research And Manufacturing Services**

- Set up in **July 2011** as a **50-50 JV company** with Belgium based Omnicem, a part of the Ajinomoto Group. The JV has set up a facility in Vizag SEZ for manufacturing of high-value APIs for Innovators and Brand Leaders on a contract manufacturing basis.

❑ **JV strategy**

- To provide a **cost effective manufacturing base to innovators for their products.**

❑ **Progress**


- FY 16-17 is the first full year of operations with INR 2,003 Mn with INR Rs 249 Mn profit
- Planning Capacity expansion

❑ **Growth from CRAMS business**

- USFDA inspected the facility with 6 observations. Response was submitted and EIR is awaited.
- Healthy Business pipeline with Innovator products



# GRANULES Group Structure and Manufacturing Capabilities




Value Chain	Facility Location	Installed Capacity	Approvals
<b>API</b>	Bonthapally	18,000 TPA	U.S. FDA, EDQM, WHO GMP
	Jeedimetla	3,560 TPA	U.S. FDA, EDQM, COFEPRIS, WHO GMP, HALAL
	Jingmen, China (Biocause JV)	4,800 TPA	U.S. FDA, MHRA, CFDA
	Vizag	285 KL	U.S. FDA, KFDA, EU GMP, WHO GMP
	Vizag SEZ (OmniChem - CRAMs JV)	152 KL	
<b>PFI</b>	Gagillapur	17,200 TPA	U.S. FDA, COFEPRIS, TGA
	Jeedimetla	1,200 TPA	HALAL
<b>FD</b>	Gagillapur	18 Bn	U.S. FDA, MCC, COFEPRIS, TGA
	Virginia, USA	0.5 Bn	
<b>API Intermediates</b>	Bonthapally	61.5 KL	






# GRANULES Consolidated Revenue Break-up for Q4FY17


V  
E  
R  
T  
I  
C  
A  
L  
  
W  
I  
S  
E




## PRODUCTION DETAILS



M  
O  
L  
E  
C  
U  
L  
E  
  
W  
I  
S  
E



G  
E  
O  
G  
R  
A  
P  
H  
Y  
  
W  
I  
S  
E




# PARA – Paracetamol; MF – Metformin; IBU – Ibuprofen; GUAI – Guaifenesin; MCB – Methocarbamol; NAP – Naproxen


## Break up of Revenue as per IND AS

V  
E  
R  
T  
I  
C  
A  
L  
  
W  
I  
S  
E


**FY17**




**FY16**



**MOLECULE WISE**




**GEOGRAPHY WISE**



# PARA – Paracetamol; MF – Metformin; IBU – Ibuprofen; GUAI – Guaifenesin; MCB – Methocarbamol

## Break up of Revenue as per IND AS






# All numbers are in INR Mn



##All the numbers for FY'16 and FY'17 are as per Ind AS. Numbers from FY11 to FY15 are based on I Gaap.

## Consolidated Financial Snapshot (INR Mn)



	FY16	FY17
Income from Operation	13,829	14,353
Material Cost	7,250	6,796
Other Operating Exp.	3,816	4,568
Other Income	52	99
EBITDA	2,815	3,088
EBITDA Margin (%)	20.4%	21.5%
EBITDA Growth (Y-o-Y)		10%
Depreciation	584	715
Finance Cost	371	323
Tax	611	652
PAT	1,230	1,645
PAT Margin (%)	8.9%	11.5%
PAT Growth (Y-o-Y)		34%
	Mar'16	Mar'17
Net Worth	6,616	9,036
Debt:		
Long-term Debt	2,485	1,827
Short-term Debt	3,929	4,738
Gross Block	8,230	9,836
CWIP	766	2,605
Total Current Assets	8,180	8,351
Total Current Liabilities	6,547	7,848



## Granules Omnichem



## Granules Biocause



Granules has 50% equity share in both the JVs.



**Mr. C. Krishna Prasad** - Chairman and Managing Director

Mr. Prasad is the Founder of Granules and has three decades of experience in the pharmaceutical industry. In 1984, he set up a Paracetamol manufacturing facility, focused on capital and process efficiency. Pharmaceutical Formulations Intermediates (PFIs) as a cost efficient product for global formulations manufacturers, a concept pioneered and popularized by him.




**Mrs. Uma Devi Chigurupati** - Executive Director

Mrs. Uma has rich experience of 30 years in various fields. Mrs. Uma with Mr. C. Krishna Prasad had co-founded Triton Laboratories Private Limited in the year 1984, which was later amalgamated with Granules India Limited. Presently, she is spear heading CSR activities and HR initiatives.



**Dr. Prasada Raju** - Executive Director

Dr. Prasada Raju has over two decades of techno commercial experience in Global pharmaceutical space. His previous experience at Dr. Reddy's encompasses new product development, foster strategic partnerships, drive synergies between Industry and Academia, new geography expansions, IP driven early Product Portfolio Development and Program Management.



**Mr. VVS Murthy** - Chief Financial Officer

Mr. Murthy has three decades of finance experience across various industries including nearly two decades in Pharmaceuticals. Mr. Murthy previously was Group Chief Financial Officer at Dishman Pharmaceuticals which encompassed Indian operations and 9 international operations. Prior to that, Mr. Murthy was VP – Finance at Dr. Reddy's where he had extensive roles including several international M&A transactions.



**Mr. Sreekanth Muttineni** - Chief Operating Officer

Mr Sreekanth Muttineni joined Granules India in September 2016. During nine year tenure with Lupin Ltd, he was responsible for manufacturing operations. Prior to that, Mr. Muttineni had worked at Aurobindo Pharma Ltd as General Manager – Operations and led the establishment of generic pharmaceutical facilities and commercialization.



**Mr. Stefan Lohle** - Chief Marketing Officer

Mr. Lohle has over two decades of experience in the Pharmaceutical industry. Mr Lohle has been associated with Granules since 2001 and previously was Head of Latin American Operations, where he primarily focused on the PFI Business. Mr Lohle previously served at Kimberly Clark Corporation for New Project Development.



The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Granules India Limited.

For Further information, please visit:

[www.granulesindia.com](http://www.granulesindia.com)

Investor Relations contact:

Sumanta Bajpayee

Tel: 040-30663572

Email: [sumanta.bajpayee@granulesindia.com](mailto:sumanta.bajpayee@granulesindia.com)